<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261546</url>
  </required_header>
  <id_info>
    <org_study_id>Hospital Infanta Sofia</org_study_id>
    <secondary_id>2009-012963-33</secondary_id>
    <nct_id>NCT01261546</nct_id>
  </id_info>
  <brief_title>Clinical Trial Corticoids For Empyema And Pleural Effusion In Children</brief_title>
  <acronym>CORTEEC</acronym>
  <official_title>MULTICENTRIC, PHASE II, CLINICAL TRIAL CORTICOIDS FOR EMPYEMA AND PLEURAL EFFUSION IN CHILDREN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Infanta Sofia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatrics Spanish Association (Madrid and Castilla-La Mancha Pediatric Association)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Ministry of Health.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Infanta Sofia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY JUSTIFICATION

        1. Scientific evidence of the usefulness of corticosteroid use for infectious diseases:
           Corticosteroids along with antibiotic use improve survival in some infectious processes
           provide long term benefits and improve symptoms in many others.

        2. Clinical Observation: the investigators observed that patients with parapneumonic
           pleural effusion and associated bronchospasm who were treated with corticosteroids for
           their bronchospasm, evolved to healing before patients who were not treated with
           corticosteroids (average admission days 10 vs. 17).

        3. Rationale: the anti-inflammatory effect has been the rationale for the use of
           dexamethasone as an inhibitor of the inflammatory response observed after the first dose
           of parenteral antibiotic in bacterial meningitis. A similar effect is likely to occur in
           pneumonia with pleural effusion. It can be therefore hypothesized that Dexamethasone
           could inhibit an excessive inflammatory response by mesothelial and inflammatory cells
           during the early phases of parapneumonic empyema, reducing its severity and hence its
           complications.

      OBJECTIVES

        1. Principal: to investigate if dexamethasone 0,25mg/kg q.i.d. added to standard antibiotic
           therapy reduces time to resolution of parapneumonic pleural effusion.

        2. Secondary:

      2.1. Evaluate the effect of dexamethasone 0,25mg/kg q.i.d. added to standard antibiotic
      therapy on the development of complications during pleural effusion episode.

      2.2. Evaluate the incidence of severe and non severe adverse events associated with the new
      treatment versus standard therapy.

      METHODS

        1. Study design: exploratory (pilot), randomized, double blinded, placebo controlled,
           parallel stratified design, multicentric.

        2. Participating Hospitals (n=56, 7 patients per center):

             -  Hospital Infanta Sofía (S. Sebastián de los Reyes, Madrid).

             -  Hospital Universitario de Getafe

             -  Hospital Universitario Ramón y Cajal, Madrid.

             -  Hospital Universitario Materno-Infantil Carlos Haya, Málaga.

             -  Hospital Infantil La Paz, Madrid.

             -  Hospital U. Gregorio Marañón

             -  Hospital U. Príncipe de Asturias

             -  Hospital Virgen de la Salud, Toledo

        3. Endpoints:

           3.1. Primary: time to resolution. 3.2. Secondary endpoints:

             1. Effectiveness: number of children with complications.

             2. Safety (expected number: none). i) Hyperglycemia ii) Signs of gastrointestinal
                bleeding iii) Need of transfusion iv) Oropharyngeal Candidiasis v) Allergic
                reaction vi) Other adverse reactions described in the Medication Guide.

        4. Treatment arms:

      3.1. Control (0)

        -  Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.

        -  Cefotaxime 150 mg/kg, IV, q.d. until discharge criteria are present.

        -  Ranitidine 5 mg/kg IV, q.d. for 2 days.

        -  Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.

      3.2. Study treatment: (1)

        -  dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.

        -  Cefotaxime 150 mg/kg, IV, q.d. until discharge criteria are present

        -  Ranitidine 5 mg/kg IV, q.d. for 2 days

        -  Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.

           4. INCLUSION CRITERIA

        -  Patients between 1 and 14 year old.

        -  Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever and
           radiological consolidation.

        -  Evidence of pleural effusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to resolution</measure>
    <time_frame>1 month after admission</time_frame>
    <description>days from diagnosis until criteria for cure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of children with complications.</measure>
    <time_frame>3 months after diagnosis</time_frame>
    <description>number of children with complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children with complications attributable to corticoids</measure>
    <time_frame>3 months</time_frame>
    <description>Hyperglycemia Signs of gastrointestinal bleeding Need of transfusion Oropharyngeal Candidiasis Allergic reaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Parapneumonic Pleural Effusion</condition>
  <condition>Empyema</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present
Ranitidine 5 mg/kg IV, q.d. for 2 days
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.
Ranitidine 5 mg/kg IV, q.d. for 2 days.
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present
Ranitidine 5 mg/kg IV, q.d. for 2 days
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.
Ranitidine 5 mg/kg IV, q.d. for 2 days.
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 1 and 14 year old.

          -  Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever
             and radiological consolidation.

          -  Evidence of pleural effusion.

        Exclusion Criteria:

          -  Allergy to any of the drugs included in the study.

          -  Immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Castilla La Mancha</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Principe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofia</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28037</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pleural effusion, empyema, corticoids, dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Empyema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

